Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

Completed

• Conditions: Non Small Cell Lung Cancer

• Registration Number: NCT01167972
• Lead Sponsor: AstraZeneca

Brief Summary

The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.

Detailed Description

MSD

Study Timeline

• Study First Submitted: 2010-07-20
• Study First Submitted QC: 2010-07-21
• Study First Posted: 2010-07-22
• Study Start: 2010-09
• Status Verified: 2012-09
• Primary Completion: 2012-09
• Study Completion: 2012-09
• Last Update Submitted: 2012-09-07
• Last Update Posted: 2012-09-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• Patient with lung cancer (Non Small Cell Lung Cancer adenocarcinoma)
• Patient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed

Exclusion Criteria

• Assessment of mutational status of EGFR is not done

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma	At baseline

Secondary Outcome Measures

Name	Time	Method
Describe the therapeutic management according to the mutational status (EGFR M +, EGFR M- and Mx).	12 months / At each visit
Describe the therapeutic management of patients with EGFR M +.	12 months / At each visit
Describe the clinical course of patients EGFR-M +, treated for first-line treatment, and then 2nd line treatment, until 31-AUG-2012	12 months / At each visit

Trial Locations

Locations (1)

Research Site; 🇫🇷 Yerres, France